NuVasive’s acquisition of Ellipse represents its entry into the early onset and idiopathic scoliosis treatment arena, and could lead to partnerships in the treatment of trauma and knee osteoarthritis.
Ellipse’s magnetically-adjustable implant systems are based on its MAGnetic External Control (MAGEC®) technology, and include MAGEC−EOS spinal bracing and distraction for treatment of early onset scoliosis and the PRECICE® limb lengthening system.
The acquisition is expected to close in mid-1Q16.
Having agreed to be acquired by NuVasive, Ellipse Technologies has withdrawn plans for a US $75MM initial public offering filed in 4Q15.
NuVasive's acquisition of Ellipse represents its entry into the early onset and idiopathic scoliosis treatment arena, and could lead to partnerships in the treatment of...
Having agreed to be acquired by NuVasive, Ellipse Technologies has withdrawn plans for a US $75MM initial public offering filed in 4Q15.
NuVasive’s acquisition of Ellipse represents its entry into the early onset and idiopathic scoliosis treatment arena, and could lead to partnerships in the treatment of trauma and knee osteoarthritis.
Ellipse’s magnetically-adjustable implant systems are based on its MAGnetic External Control (MAGEC®) technology, and include MAGEC−EOS spinal bracing and distraction for treatment of early onset scoliosis and the PRECICE® limb lengthening system.
The acquisition is expected to close in mid-1Q16.
You’ve reached your limit.
We’re glad you’re finding value in our content — and we’d love for you to keep going.
Subscribe now for unlimited access to orthopedic business intelligence.
Copy to clipboard 
